182 related articles for article (PubMed ID: 15855175)
21. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
[TBL] [Abstract][Full Text] [Related]
24. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
Lin CC; Cheng AL; Hsu CH; Lu YS; Hsu C; Yeh KH; Wu CY; Huang CS; Yang CH
Anticancer Res; 2007; 27(1B):641-5. PubMed ID: 17348454
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Matsuda T; Ogino K; Hiroyoshi M; Fujita H; Itoh T; Toyama H; Kawai Y; Makita D; Tsunemi K; Moritomo H; Nakamura T
Gan To Kagaku Ryoho; 2006 Jun; 33(6):783-7. PubMed ID: 16770097
[TBL] [Abstract][Full Text] [Related]
27. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
28. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
29. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
31. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
[TBL] [Abstract][Full Text] [Related]
32. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
[TBL] [Abstract][Full Text] [Related]
33. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
[TBL] [Abstract][Full Text] [Related]
34. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
37. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
[TBL] [Abstract][Full Text] [Related]
38. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]